Portfolio company Quartet Medicine Announces Strategic Partnership with Merck
Apollo Endosurgery receives FDA approval for an innovative non-surgical weight loss solution
Portfolio company Tigercat Pharma announces positive Phase II results
Apollo Endosurgery’s LAP-BAND System featured on “The Dr. Oz Show”
miRagen compound reverses pulmonary fibrosis
BiO2 enrolls subjects in Early Feasibility Pilot Study
Tigercat Pharma doses first patient in Prurigo Nodularis Phase II Study
Portfolio company Apollo Endosurgery completes acquisition of obesity intervention division
Remeditex supports promising research with San Antonio scientist.
Portfolio company miRagen named one of the most promising biotech companies of 2012.
Remeditex Ventures funds innovative medical device company.
Remeditex Ventures leads Series B financing in Boulder based microRNA company, miRagen.
Remeditex is a key investor in an Austin based medical device company.
Remeditex supports an early stage Dallas-based oncology company